ResMed Is Maintained at Overweight by Keybanc
ResMed Price Target Raised 1.8% to A$45.60/Share by Barrenjoey
ResMed Is Maintained at Overweight by Keybanc
Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Buy From Morgan Stanley
Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Buy From Goldman Sachs
Citi Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Goldman Sachs Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Raised to Buy From Neutral by Citigroup
ResMed Is Maintained at Hold by Stifel
Morgans Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Raised 5.5% to A$43.60/Share by Morgans
ResMed Cut to Mkt Weight From Overweight by Wilsons >RMD.AU
ResMed Is Maintained at Neutral by Piper Sandler
ResMed Price Target Raised 2.1% to A$44.80/Share by Barrenjoey
ResMed Price Target Raised 3% to A$238.00/Share by RBC Capital Markets
J.P. Morgan Remains a Buy on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
UBS Keeps Their Hold Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Citi Keeps Their Hold Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Initiated at Buy by Goldman Sachs
ResMed Initiated at Hold by Stifel